An observational study in Bleeding and Tooth Extraction, sponsored by Bezmialem Vakif University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 14 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by Bezmialem Vakif University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Hemorrhage with a site in Turkey — 10 open to participants now, 11 under way, 5 of them phase 3. Hemorrhage · Turkey.
Among the 57 studies in Hemorrhage with a site in Turkey, this one is the 16th largest by planned enrollment of the 16 observational ones that give a count, is one of 9 that started in 2025, is one of 16 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 44th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →10 of the 57 studies in Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:
Grand Shuyang Life Sciences (Chengdu) Co., Ltd. · Sites in Turkey
Ages 18–65
Takeda · Sites in Turkey, United States, Australia and 12 more countries
Ages 18+
Takeda · Sites in Turkey, United States, Australia and 15 more countries
Ages 18+
University of Gaziantep · Sites in Turkey
Ages 18–50
Pfizer · Sites in Turkey, United States, Australia and 11 more countries
Ages 18+ · Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 14 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 215 across 397 observational studies indexed under Hemorrhage.
Median enrollment 102 across the 41 interventional studies, 73 across the 16 observational. Of the 40 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 57 have an industry lead sponsor. The 10 most frequent:
Bezmialem Vakif University is the lead sponsor of 359 studies on the registry; 61 are open to participants now.
Bezmialem Vakif University has 5 studies filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Hemorrhage with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233213Phase 3Grand Shuyang Life Sciences (Chengdu) Co., Ltd.An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 57 studies in Hemorrhage with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Tranexamic acid (TXA) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. It is a relatively safe drug with minimal significant side effects. The most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. The increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. Based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. To mitigate systemic absorption and minimize undesirable side effects, TXA can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.
Topical TXA irrigation has recently begun to be used intraoperatively. In a study conducted by Eftekharian et al., the application of intraoperative 1% TXA irrigation solution during bimaxillary orthognathic surgery was found to be significantly associated with a reduction in intraoperative blood loss compared to placebo. Additionally, the topical application of TXA to the maxillary sinus during endoscopic sinus surgery has been shown to reduce intraoperative blood loss. In the current literature, the use of tranexamic acid irrigation during tooth extraction under local anesthesia has not been reported. Our study aims to demonstrate the effectiveness of TXA irrigation during the extraction of bone-retained teeth and its effect on postoperative edema.
community sample
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the double-blind, controlled, randomized study, only saline will be used as the irrigation solution in the control group patients.
Drug: saline irrigation
In the double-blind, controlled, randomized study, saline with tranexamic acid solution will be used as the irrigation solution in the study group patients.
Drug: Tranexamic acid
in the study group, a combination of two ampules of Tranexamic acid solution mixed with saline will be used. Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
In control group, saline will be used for irrigation.Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
postoperative edema
Anatomical landmarks, including gonion (Go), ala nasi (AN), tragus (Tr), and lateral canthus (Ka), will be marked with methylene blue for measurement purposes. The distances between lateral canthus and gonion, tragus and commissure, and gonion and ala nasi will be measured preoperatively (just before the procedure begins) and on postoperative day 3, when maximum edema is expected, and the values will be recorded.
Time frame: 3 days
intraoperative bleeding
During the surgery, the total aspirate volume collected in the suction device will be recorded. By subtracting the amount of irrigation solution used, the amount of bleeding (in cc) will be calculated separately for the right and left sides and documented.
Time frame: during the surgery time
intraoperative vision scale
Intraoperatively, based on the evaluation of surgical bleeding and surgical comfort, the surgeon will be asked to rate the surgical field on a 5-point scale after irrigation. An average score will be calculated postoperatively to determine the surgical field evaluation score. Separate scoring will be performed for both the right and left sides. Scale: 1. \- Intense bleeding, making it impossible to isolate the tooth. 2. \- Severe bleeding, making isolation difficult. 3. \- Moderate bleeding, causing slight difficulty in isolation. 4. \- Mild bleeding, isolation is unaffected. 5. \- No bleeding or an almost bloodless surgical field.
Time frame: during the surgery
Started Jan 2025 (actual). Primary completion is estimated for Mar 2026, 14 months after the start.
Of 134 non-industry observational studies under Hemorrhage, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 78. This study's planned 14 months is below that.
Counting every sponsor, half of 158 studies reached it within 33 months; a quarter within 15 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.